In a study of trametinib (a MEK inhibitor) in patients with MM with BRAF, NRAS, or KRAS mutations, researchers observed that the clinical disease progression was associated with an increase in VAFs of NRAS and KRAS mutations, indicating the involvement of a MAPK pathway-dependent mechanism in the resistance to trametinib. This evidence concerns the gene KRAS and Miyoshi myopathy.